Качество жизни и спектр симптомов у больных миелофиброзом на фоне терапии: данные клинической практики

The aim of the study was to evaluate the quality of life (QoL) and symptoms in patients with myelofibrosis (MF). 93 patients with MF who participated in the multicenter observational study “Quality of life and symptoms in myelofibrosis: validation of the symptom assessment tool for patients with myelofibrosis” (2014–2015) were enrolled in the analysis. 62 patients received best available treatment (BAT) and 31 patients received ruxolitinib. All the patients filled out the SF-36, CSP-Myelofibrosis Module and Patient Global Impression of Change (PGIC) tools. In the real-world study in MF patients QoL was demonstrated to be significantly worse than in healthy controls; more than one third of patients had significant or severe QoL impairment. Patients treated with ruxolitinib had better QoL and lower symptom severity as compared to BAT patients. Decline of activity appeared to be the major symptom which significantly reduced QoL in MF patients. QoL and symptom data in MF patients during treatment in a real world setting may be a solid supplement to clinical variables and may contribute to better disease control in accordance with the principles of risk-adaptive therapy.